☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
BioXcel
BioXcel Publishes Results of BXCL501 in P-III (SERENITY II) Trial for the Treatment of Bipolar Disorders in the JAMA
February 23, 2022
BioXcel Initiates P-III (TRANQUILITY) Program of BXCL501 for the Acute Treatment of Agitation in Patients with Alzheimer’s Disease
December 16, 2021
PharmaShots Weekly Snapshots (May 17 - 21, 2021)
May 21, 2021
PharmaShots Weekly Snapshots (Mar 29 - Apr 02, 2021)
April 2, 2021
PharmaShots Weekly Snapshots (Mar 15 - 19, 2021)
March 19, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.
